A recent study published in Nature has revealed that administering SARS-CoV-2 mRNA vaccines to cancer patients alongside immune checkpoint inhibitors (ICIs) can significantly enhance overall survival. This combination therapy appears to activate innate immune responses—particularly type I interferons and antigen-presenting cells—effectively “priming” tumors to respond more robustly to ICIs. Remarkably, even tumors traditionally considered “cold”—those with low immune cell infiltration—became more responsive, suggesting that an off-the-shelf infectious-disease vaccine can serve as a general immune primer for cancer therapy.
Key Findings:
Enhanced Immune Activation: SARS-CoV-2 mRNA vaccines increased type I interferon levels and activated myeloid-lymphoid pathways in both preclinical models and human subjects.
Improved Tumor Response: Increased PD-L1 expression on tumors was observed, enhancing their susceptibility to ICIs.
Survival Benefits: Patients who received the vaccine within 100 days before starting ICI therapy experienced significantly improved median and three-year overall survival rates.
Broad Applicability: The therapeutic benefit was consistent across various tumor types, including those previously deemed immunologically cold.
These findings underscore the potential of leveraging pre-existing immune memory against viruses as a powerful strategy to enhance cancer immunotherapy. By repurposing an existing vaccine, this approach offers a cost-effective and scalable method to boost the efficacy of cancer treatments.
Read More:
Grippin, A.J., Marconi, C., Copling, S. et al. SARS-CoV-2 mRNA vaccines sensitize tumors to immune checkpoint blockade. Nature (2025). https://doi.org/10.1038/s41586-025-09655-y
SHARE
